About
CARDIONOVUM GmbH is a German medical device company that specializes in innovative cardiovascular therapies. Founded by Dr. Michael Orlowski, the company is known for pioneering the first CE-approved Drug-Eluting Balloon (DEB) in 2007, which marked a significant advancement in minimally invasive cardiovascular treatment. The company develops and manufactures drug-coated balloon (DCB) devices and drug-eluting stent (DES) systems aimed at addressing complex cardiovascular conditions. Their product portfolio includes devices for peripheral vascular interventions, such as the LEGFLOW RX/OTW® and APERTO OTW®, as well as coronary vascular interventions like the RESTORE DEB® and XLIMUS®. CARDIONOVUM focuses on maintaining technology leadership and improving patient outcomes through continuous research and development. Headquartered in Bonn, Germany, CARDIONOVUM employs around 32 people and generates approximately $8.8 million in revenue. Their products are clinically proven and widely used by healthcare providers specializing in cardiovascular interventions, including hospitals and interventional cardiologists.
Technologies
Keywords
Company Information
-
Employees 26
-
Founded 2010
Location
2 Am Bonner Bogen, Bonn, North Rhine-Westphalia, Germany, 53227